Evidence map›Paper›PMID 36759141›Full record

SynthesisAJNR. American journal of neuroradiology2023

MRI for Cushing Disease: A Systematic Review.

M Castle-Kirszbaum, S Amukotuwa, P Fuller, T Goldschlager, A Gonzalvo, J Kam, C Y Kow, M D Shi, S Stuckey

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in AJNR. American journal of neuroradiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Prospective Multicenter Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

M Castle-KirszbaumFrom the Departments of Neurosurgery (M.C.-K., T.G., J.K., C.Y.K.) mdck.journal@gmail.com.ORCID 0000-0003-1769-2712
S AmukotuwaRadiology (S.A.).ORCID 0000-0002-1678-3930
P FullerEndocrinology (P.F.).
T GoldschlagerFrom the Departments of Neurosurgery (M.C.-K., T.G., J.K., C.Y.K.).ORCID 0000-0001-9572-0227
A GonzalvoDepartment of Neurosurgery (A.G., J.K.), Austin Hospital, Melbourne, Australia.
J KamFrom the Departments of Neurosurgery (M.C.-K., T.G., J.K., C.Y.K.).
C Y KowFrom the Departments of Neurosurgery (M.C.-K., T.G., J.K., C.Y.K.).ORCID 0000-0002-3897-8368
M D ShiBarwon Health (M.D.S.), Geelong, Australia.ORCID 0000-0002-3773-7191
S StuckeyDepartment of Radiology (S.S.), Peter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0001-7181-6443
Austin Hospital · AUMonash Health · AUAnna Needs Neuroblastoma Answers · USBarwon Health · AUHudson Institute · USNorwegian Womens Public Health Association · NOPeter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMR imaging is key in the diagnostic work-up of Cushing disease. The sensitivity of MR imaging in Cushing disease is not known nor is the prognostic significance of "MR imaging-negative" disease. PURPOSE: Our aim was to determine the overall sensitivity and prognostic significance of MR imaging localization of Cushing disease. DATA SOURCES: We performed a systematic review of the MEDLINE and PubMed databases for cohort studies reporting the sensitivity of MR imaging for the detection of adenomas in Cushing disease. STUDY SELECTION: This study included 57 studies, comprising 5651 patients. DATA ANALYSIS: Risk of bias was assessed using the methodological index for non-randomized studies criteria. Meta-analysis of proportions and pooled subgroup analysis were performed. DATA SYNTHESIS: Overall sensitivity was 73.4% (95% CI, 68.8%-77.7%), and the sensitivity for microadenomas was 70.6% (66.2%-74.6%). There was a trend toward greater sensitivity in more recent studies and with the use of higher-field-strength scanners. Thinner-section acquisitions and gadolinium-enhanced imaging, particularly dynamic sequences, also increased the sensitivity. The use of FLAIR and newer 3D spoiled gradient-echo and FSE sequences, such as spoiled gradient-echo sequences and sampling perfection with application-optimized contrasts by using different flip angle evolutions, may further increase the sensitivity but appear complementary to standard 2D spin-echo sequences. MR imaging detection conferred a 2.63-fold (95% CI, 2.06-3.35-fold) increase in remission for microadenomas compared with MR imaging-negative Cushing disease. LIMITATIONS: Pooled analysis is limited by heterogeneity among studies. We could not account for variation in image interpretation and tumor characteristics.

conclusionsDetection on MR imaging improves the chances of curative resection of adenomas in Cushing disease. The evolution of MR imaging technology has improved the sensitivity for adenoma detection. Given the prognostic importance of MR imaging localization, further effort should be made to improve MR imaging protocols for Cushing disease.

Indexed as

AdenomaPituitary ACTH HypersecretionPituitary NeoplasmsContrast MediaHumansMagnetic Resonance ImagingSensitivity and SpecificityContrast Media

Identifiers

PMID36759141
PMCPMC10187804
OpenAlexW4319724091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.